Hester Biosciences Q1 FY26 Concall Decoded: Vaccines Delayed, Profits Delivered

Opening Hook

When you make vaccines for animals, your fortunes are tied to both the government’s timing and the cows’ mood swings. Hester Biosciences entered Q1 FY26 expecting a smooth run but got a surprise: Indian immunization orders decided to take a nap. Yet, like a well-trained vet, the company revived its profits with a strong African comeback.

Here’s what we decoded from the call where management juggled delays, defended margins, and promised a stronger Q2.

At a Glance

• Revenue ₹63 Cr (standalone) – 14% down, thanks to tender delays.
• PAT ₹17 Cr (standalone) – 7% down, but still standing tall.
• Africa Ops – turned a ₹5 Cr profit from last year’s losses.
• Consolidated PAT – up 100%+, proving Africa’s roar is louder than India’s snooze.
• Upcoming Avian Influenza Vaccine – stuck in regulatory limbo, like your Amazon order.

The Story So Far

Last quarter, Hester promised growth on the back of international expansion and domestic immunization programs. This quarter, institutional orders for PPR and lumpy skin vaccines (big revenue drivers) were delayed. While India stumbled, Africa sprinted: revenues jumped from ₹3 Cr to ₹17 Cr YoY, flipping losses into profit. Nepal remained steady, with occasional mood swings due to order timing.

Management also flexed its upcoming product launches—avian flu vaccine is nearly ready, pending regulatory approval, and feed supplements plus disinfectants are gaining traction. Overall, a quarter of mixed signals: domestic headaches, global tailwinds.

Management’s Key Commentary

1. On Domestic Weakness:
   “Institutional orders were deferred, not cancelled.”
   Translation: Don’t panic, cows will eventually get their shots.
2. On Africa:
   “Turnaround achieved, profits sustainable if demand continues.”
   Translation: Please pray the trend lasts.
3. On Petcare:
   “Early signs of repeat demand.”
   Translation: Dogs like us, vets like us, revenues will follow.
4. On Poultry:
   “Growth was marginal but steady.”
   Translation: Chickens are moody, but we’re hanging in.
5. On BSL-3 Facility:
   “Repurposing after COVID.”
   Translation: No more corona antigens, now it’s for animal vaccines (eventually).
6. On Strategy:
   “FY26 will see normalization